Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TFAP2A antisense RNA 2 (TFAP2A-AS2), also known as HIPSTR, is a long noncoding RNA (lncRNA) expressed from the opposite (antisense) strand within the TFAP2A gene locus. HIPSTR is a capped, nuclear-enriched, monoexonic transcript associated with chromatin and is most active in undifferentiated cells. Its promoter can be stimulated by TFAP2A but HIPSTR expression does not necessarily parallel TFAP2A expression, indicating independent regulation. HIPSTR plays a context-dependent role in developmental gene regulation: it can repress target genes in non-pluripotent cells and activate them in pluripotent cells. Expression of HIPSTR is characterized by high heterogeneity among cells, particularly in early human embryos and is most prominently found in testis and placenta tissues. Silencing of HIPSTR alters the expression of key developmental genes and disrupts differentiation patterns. Currently, there are no reported drugs, clinical biomarkers, or specific therapeutic approaches targeting HIPSTR, and its role as a therapeutic target remains unproven. TFAP2A-AS2/HIPSTR is not a receptor, enzyme, transporter, or conventional therapeutic target. It is a noncoding RNA molecule involved in epigenetic and transcriptional regulation, impacting development and differentiation rather than serving as a direct drug target. Aliases reflect different nomenclature conventions in databases and scientific literature. Molecular classification: It falls strictly under lncRNAs and is not part of other molecular target families such as receptors or kinases. Disease roles: Evidence for involvement is mostly at the level of modulating developmental gene networks and suggestive but not definitive for direct roles in cancer or developmental disorders. No information available for drugs, mechanism of action, biomarkers, or safety concerns in either research or clinical contexts as of this synthesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TFAP2A antisense RNA 2 (TFAP2A-AS2).